826 results on '"Bertoletti, Antonio"'
Search Results
302. α-Fetoprotein Impairs APC Function and Induces Their Apoptosis
303. Longitudinal Analysis of CD8 + T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy
304. Erratum to “Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B”
305. Underwhelming the Immune Response: Effect of Slow Virus Growth on CD8 + -T-Lymphocyte Responses
306. Underwhelming the Immune Response: Effect of Slow Virus Growth on CD8+-T-Lymphocyte Responses
307. Reconstitution of Hepatitis B Virus (HBV)–Specific T Cell Responses with Treatment of Human Immunodeficiency Virus/HBV Coinfection
308. Greater CD8+ TCR Heterogeneity and Functional Flexibility in HIV-2 Compared to HIV-1 Infection
309. Tracking the Source of the Hepatitis B Virus–Specific CD8 T Cells during Lamivudine Treatment
310. A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines
311. Role of the Immune Response in Hepatitis B.
312. Escaping High Viral Load Exhaustion
313. T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection
314. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?
315. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection
316. Cytotoxic T Cells from Human Immunodeficiency Virus Type 2-Infected Patients Frequently Cross-React with Different Human Immunodeficiency Virus Type 1 Clades
317. SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity
318. Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance?
319. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection.
320. Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases.
321. Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen
322. T cell fitness in the liver: How can T cells keep it up?
323. Reconstitution of Hepatitis B Virus (HBV)--Specific T Cell Responses with Treatment of Human Immunodeficiency Virus/ HBV Coinfection.
324. Kinetics of the immune response during HBV and HCV infection.
325. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy.
326. Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms.
327. How can the cellular immune response control hepatitis B virus replication?
328. Personalized Armored TCR-Redirected T Cell Therapy for Liver/Organ Transplant with Recurrent Cancer.
329. Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV
330. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
331. Protocol to detect antigen-specific nasal-resident T cell in humans
332. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
333. HBV infection and HCC: the 'dangerous liaisons'.
334. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset
335. Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes
336. Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cure
337. Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12–17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination.
338. HBV in 2016: Global and immunotherapeutic insights into hepatitis B
339. Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3.
340. Erratum: E3 Ubiquitin ligase ZNRF4 negatively regulates NOD2 signalling and induces tolerance to MDP.
341. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant.
342. Adaptive immunity in HBV infection.
343. BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: a cohort study.
344. Corrigendum: Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire.
345. SAT-383 Rapid analysis of HBV-specific T cell secretomes reveals distinct antiviral immune profiles among chronic HBV patients.
346. LBP-009 Liver-infiltrating activated HBV-specific tissue-resident memory T cells and atypical memory B cells were correlated with acute-onchronic liver failure.
347. Favorable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapies.
348. OS-050 Therapeutic vaccine (BRII-179) induced immune response associated with HBsAg reduction in a subset of chronic hepatitis B participants.
349. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
350. Difference in sensitivity between SARS-CoV-2-specific T cell assays in patients with underlying conditions. Reply.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.